Do analysts rate DWTX or EGRX?

Dogwood Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 739.16%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dogwood Therapeutics is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DWTX or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -75.55% -40.28% Eagle Pharmaceuticals N/A N/A N/A

Do analysts rate RYM or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate VERU or EGRX?

Veru presently has a consensus target price of $24.50, indicating a potential upside of 864.57%. Given Veru's stronger consensus rating and higher possible upside, equities analysts clearly believe Veru is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERU or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Eagle Pharmaceuticals N/A N/A N/A

Does the media favor VERU or EGRX?

In the previous week, Veru and Veru both had 1 articles in the media. Veru's average media sentiment score of 0.72 beat Eagle Pharmaceuticals' score of 0.00 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GRCE or EGRX?

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 194.12%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Grace Therapeutics is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GRCE or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -36.11% -34.39% Eagle Pharmaceuticals N/A N/A N/A

Is PYRGF or EGRX more profitable?

Eagle Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets PyroGenesis Canada -115.14% N/A -60.81% Eagle Pharmaceuticals N/A N/A N/A

Does the media prefer PYRGF or EGRX?

In the previous week, PyroGenesis Canada had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 3 mentions for PyroGenesis Canada and 1 mentions for Eagle Pharmaceuticals. PyroGenesis Canada's average media sentiment score of 0.34 beat Eagle Pharmaceuticals' score of 0.00 indicating that PyroGenesis Canada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eagle Pharmaceuticals (EGRX) Competitors

$0.96 +0.01 (+1.05%)

As of 10/1/2026 09:51 AM Eastern

Compare

EGRX vs. DWTX, RYM, VERU, GRCE, and PYRGF

Should you buy Eagle Pharmaceuticals stock or one of its competitors? Eagle Pharmaceuticals's main competitors and comparable companies include Dogwood Therapeutics (DWTX), RYTHM (RYM), Veru (VERU), Grace Therapeutics (GRCE), and PyroGenesis Canada (PYRGF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eagle Pharmaceuticals compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dogwood Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 739.16%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dogwood Therapeutics is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals' return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Eagle Pharmaceuticals	N/A	N/A	N/A

Dogwood Therapeutics has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 1 mentions for Eagle Pharmaceuticals and 0 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 1.82 beat Eagle Pharmaceuticals' score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dogwood Therapeutics	Very Positive
Eagle Pharmaceuticals	Neutral

Eagle Pharmaceuticals has higher revenue and earnings than Dogwood Therapeutics. Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Eagle Pharmaceuticals	$257.55M	0.05	$35.64M	$1.18	0.81

Summary

Eagle Pharmaceuticals beats Dogwood Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to RYTHM?

RYTHM (NASDAQ:RYM) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Eagle Pharmaceuticals has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. Eagle Pharmaceuticals' return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Eagle Pharmaceuticals	N/A	N/A	N/A

In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than RYTHM. MarketBeat recorded 1 mentions for Eagle Pharmaceuticals and 0 mentions for RYTHM. RYTHM's average media sentiment score of 0.36 beat Eagle Pharmaceuticals' score of 0.00 indicating that RYTHM is being referred to more favorably in the media.

Company	Overall Sentiment
RYTHM	Neutral
Eagle Pharmaceuticals	Neutral

6.0% of RYTHM shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

RYTHM has a beta of 9.46, suggesting that its share price is 846% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.52	-$33.26M	-$10.53	N/A
Eagle Pharmaceuticals	$257.55M	0.05	$35.64M	$1.18	0.81

Summary

Eagle Pharmaceuticals beats RYTHM on 10 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Veru?

Veru (NASDAQ:VERU) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Veru presently has a consensus target price of $24.50, indicating a potential upside of 864.57%. Given Veru's stronger consensus rating and higher possible upside, equities analysts clearly believe Veru is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.56	-$22.73M	-$0.69	N/A
Eagle Pharmaceuticals	$257.55M	0.05	$35.64M	$1.18	0.81

47.2% of Veru shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Veru has a beta of -1.21, suggesting that its share price is 221% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Eagle Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Eagle Pharmaceuticals	N/A	N/A	N/A

In the previous week, Veru and Veru both had 1 articles in the media. Veru's average media sentiment score of 0.72 beat Eagle Pharmaceuticals' score of 0.00 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Eagle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eagle Pharmaceuticals beats Veru on 9 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 10.8% of Grace Therapeutics shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 194.12%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Grace Therapeutics is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals' return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Eagle Pharmaceuticals	N/A	N/A	N/A

In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 1 mentions for Eagle Pharmaceuticals and 0 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.87 beat Eagle Pharmaceuticals' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Very Positive
Eagle Pharmaceuticals	Neutral

Grace Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Eagle Pharmaceuticals	$257.55M	0.05	$35.64M	$1.18	0.81

Summary

Eagle Pharmaceuticals beats Grace Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Eagle Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Eagle Pharmaceuticals	N/A	N/A	N/A

In the previous week, PyroGenesis Canada had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 3 mentions for PyroGenesis Canada and 1 mentions for Eagle Pharmaceuticals. PyroGenesis Canada's average media sentiment score of 0.34 beat Eagle Pharmaceuticals' score of 0.00 indicating that PyroGenesis Canada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eagle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eagle Pharmaceuticals has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.66	-$21.12M	-$0.04	N/A
Eagle Pharmaceuticals	$257.55M	0.05	$35.64M	$1.18	0.81

PyroGenesis Canada has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats PyroGenesis Canada on 8 of the 12 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EGRX vs. The Competition

Export

Metric	Eagle Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.47M	$12.40B	$7.23B	$13.08B
Dividend Yield	N/A	2.63%	2.53%	15.88%
P/E Ratio	0.81	794.60	272.65	25.80
Price / Sales	0.05	752.22	607.73	90.99
Price / Cash	0.40	81.79	77.38	51.29
Price / Book	N/A	10.31	10.51	6.26
Net Income	$35.64M	$2.84B	$3.50B	$360.95M
7 Day Performance	-6.34%	-1.88%	-2.01%	-1.80%
1 Month Performance	4.92%	-6.43%	-6.41%	-4.02%
1 Year Performance	-68.00%	-3.77%	8.96%	2.18%

Eagle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EGRX Eagle Pharmaceuticals	N/A	$0.96 +1.1%	N/A	-64.4%	$12.47M	$257.55M	0.81	100	News Coverage Gap Down
DWTX Dogwood Therapeutics	3.4135 of 5 stars	$1.36 +0.4%	$12.00 +785.6%	-79.8%	$46.06M	N/A	N/A	8	Positive News
RYM RYTHM	0.2589 of 5 stars	$20.97 -1.2%	N/A	-51.4%	$45.68M	$51.01M	N/A	141
VERU Veru	2.3368 of 5 stars	$2.68 +4.5%	$24.50 +815.9%	-34.7%	$45.61M	$16.89M	N/A	230
GRCE Grace Therapeutics	2.1455 of 5 stars	$2.15 +1.7%	$6.00 +179.7%	-33.6%	$45.12M	N/A	N/A	5	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EGRX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. DWTX, RYM, VERU, GRCE, and PYRGF

How does Eagle Pharmaceuticals compare to Dogwood Therapeutics?

Summary

How does Eagle Pharmaceuticals compare to RYTHM?

Summary

How does Eagle Pharmaceuticals compare to Veru?

Summary

How does Eagle Pharmaceuticals compare to Grace Therapeutics?

Summary

How does Eagle Pharmaceuticals compare to PyroGenesis Canada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. DWTX, RYM, VERU, GRCE, and PYRGF

How does Eagle Pharmaceuticals compare to Dogwood Therapeutics?

Do insiders and institutionals hold more shares of DWTX or EGRX?

Do analysts rate DWTX or EGRX?

Is DWTX or EGRX more profitable?

Which has more risk & volatility, DWTX or EGRX?

Does the media prefer DWTX or EGRX?

Which has higher earnings and valuation, DWTX or EGRX?

Summary

How does Eagle Pharmaceuticals compare to RYTHM?

Is RYM or EGRX more profitable?

Does the media prefer RYM or EGRX?

Do insiders & institutionals hold more shares of RYM or EGRX?

Do analysts rate RYM or EGRX?

Which has more volatility & risk, RYM or EGRX?

Which has stronger valuation and earnings, RYM or EGRX?

Summary

How does Eagle Pharmaceuticals compare to Veru?

Do analysts rate VERU or EGRX?

Which has better earnings & valuation, VERU or EGRX?

Do institutionals and insiders hold more shares of VERU or EGRX?

Which has more risk and volatility, VERU or EGRX?

Is VERU or EGRX more profitable?

Does the media favor VERU or EGRX?

Summary

How does Eagle Pharmaceuticals compare to Grace Therapeutics?

Do insiders & institutionals have more ownership in GRCE or EGRX?

Do analysts prefer GRCE or EGRX?

Is GRCE or EGRX more profitable?

Does the media prefer GRCE or EGRX?

Which has more volatility and risk, GRCE or EGRX?

Which has higher earnings and valuation, GRCE or EGRX?

Summary

How does Eagle Pharmaceuticals compare to PyroGenesis Canada?

Is PYRGF or EGRX more profitable?

Does the media prefer PYRGF or EGRX?

Which has higher valuation & earnings, PYRGF or EGRX?

Which has more risk and volatility, PYRGF or EGRX?

Do institutionals & insiders hold more shares of PYRGF or EGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools